Oral PCSK9 inhibitor enlicitide cuts LDL 56-60% in phase 3 trials atop statins
Key Questions
What LDL reduction did enlicitide achieve in phase 3 trials?
Merck's CORALreef phase 3 trials showed enlicitide reduced LDL by 56-60% on top of statins, with additional 26% Lp(a) lowering.
What regulatory status has enlicitide received?
The oral PCSK9 inhibitor has been granted FDA fast-track designation and expands options for primary and secondary prevention post-guideline.
How does enlicitide fit with other emerging therapies?
It aligns with trials like VESALIUS and inclisiran, supporting dual stacking strategies and practical oral dosing considerations for broader access.
Merck CORALreef ph3 ACC.26: 64.6%+ LDL/26% Lp(a); expands primary/sec post-guideline; FDA fast-track. Aligns with VESALIUS/inclisiran/LEROCHOL/dual stacking; practical dosing and access considerations. Recent article on engineered enzymes for manufacturing (not practice-changing).
Sources (2)
Updated May 29, 2026